Drug Trial Radar · NCT06493045
First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
May 16, 2024
Primary completion
Feb 7, 2025
Study completion Feb 7, 2025
Sponsor
- Lead sponsor
- Integrative Research Laboratories ABIndustry
- Sponsor type
- Industry
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, First-In-Human study evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.
Conditions
- Not Determined
Interventions
IRL757Drug
IRL757 capsule
PlaceboDrug
Placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of Frequency, Seriousness and Intensity of Adverse EventsTime frame: Until 5-10 days after IMP administration
- Description of Physical Examination FindingsTime frame: Until 5-10 days after IMP administration
- Description of Electrocardiogram FindingsTime frame: Until 5-10 days after IMP administration
- Description of Vital Signs FindingsTime frame: Until 5-10 days after IMP administration
- Description of Safety Laboratory MeasurementsTime frame: Until 5-10 days after IMP administration
- Description of C-SSRS (Columbia Suicide Severity Rating Scale) FindingsTime frame: Until 5-10 days after IMP administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CTC Clinical Trial Consultants AB, Uppsala University Hospital
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.